Valuation: Epigenomics AG

Market Cap 763K 870K 707K 650K 1.23M 83.26M 1.25M 8.42M 3.3M 40.89M 3.27M 3.2M 141M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 11.73M 13.37M 10.86M 10M 18.91M 1.28B 19.28M 129M 50.78M 629M 50.22M 49.12M 2.17B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
70.75%
Yield 2024 *
-
Yield 2025 -
1 day+1.15%
1 week-31.78%
Current month+1.15%
1 month+1.15%
3 months-4.86%
6 months-2.44%
Current year-2.22%
1 week 0.87
Extreme 0.87
1.1
1 month 0.87
Extreme 0.87
1.4
Current year 0.84
Extreme 0.84
1.55
1 year 0.84
Extreme 0.84
1.59
3 years 0.5
Extreme 0.5
4.2
5 years 0.5
Extreme 0.5
25.88
10 years 0.5
Extreme 0.5
1,187.36
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 2024-01-31
Director TitleAgeSince
Chairman 58 2023-02-28
Director/Board Member 55 2020-05-31
Director/Board Member 56 2024-02-04
Date Insider Type Main position Quantity % Market Cap.
22-12-28Buy

Chief Financial Officer

2,000 0.0122%
21-09-06Sell

Director

7,790 0.0637%
21-01-31Buy

Chairman

6,355 0.1079%
Change 5-day change 1-year change 3-year change Capi.($)
+1.15%-31.78%+3.53%-76.53% 872K
+0.69%-0.76%+115.97%+101.81% 4.55B
+0.12%-1.12%+84.07%+188.86% 3.37B
+1.08%-0.08%-26.22%-38.11% 2.05B
-2.96%-1.35%+105.65%-46.18% 1.89B
-0.02%-1.79%+42.56%+182.29% 1.47B
+4.68%+7.97%+138.58%-50.43% 898M
-1.90%-3.07%-11.78%+39.46% 880M
+2.24%+3.33%-0.46% - 487M
-2.32%-5.43%-38.25%-19.55% 483M
Average +0.28%-4.05%+41.36%+31.29% 1.61B
Weighted average by Cap. +0.17%-0.08%+69.32%+75.85%

Financials

2024 2025
Net sales - 24K 27.36K 22.23K 20.45K 38.69K 2.62M 39.44K 265K 104K 1.29M 103K 101K 4.44M
Net income -3.35M -3.82M -3.1M -2.86M -5.4M -366M -5.51M -37M -14.51M -180M -14.35M -14.04M -620M -314K -358K -291K -268K -506K -34.26M -516K -3.47M -1.36M -16.83M -1.34M -1.31M -58.11M
Net Debt 10.46M 11.92M 9.68M 8.91M 16.85M 1.14B 17.18M 115M 45.26M 560M 44.76M 43.78M 1.93B 10.97M 12.5M 10.16M 9.35M 17.68M 1.2B 18.02M 121M 47.48M 588M 46.95M 45.93M 2.03B
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
3
Date Price Change Volume
26-07-13 0.8800 +1.15% 590
26-07-10 €0.8700 0.00% 4
26-07-09 €0.8700 -0.57% 0
26-07-08 €0.8750 -20.45% 500
26-07-07 €1.100 -14.73% 0

Annual profits - Rate of surprise